Microbiome Therapeutics Patent Landscape 2026
Microbiome Therapeutics Patent Landscape in 2026
A corpus of 10,017 patent families reveals a field past its 2020 filing peak, with 4D Pharma Research leading a moderately concentrated top tier where the five largest filers hold 20% of the hundred largest filers’ combined output. The United States is the dominant filing jurisdiction, and medicinal preparations remain the dominant technology class, while adjacent branches in functional foods, diagnostics, and peptides carry meaningfully lower coverage.
4D Pharma leads a moderately concentrated top tier across 10,017 patent families
4D Pharma Research Ltd holds the leading position with 389 patent families, ahead of Evelo Biosciences (254), Nestlé (245), the Regents of the University of California (238), and SNIPR Tech (237). The top five filers together account for 20% of the hundred largest filers’ combined total, signalling moderate rather than extreme concentration.
A meaningful tier gap separates the top five from ranks six through ten, which range from 197 (INSERM) to 128 (Seres Therapeutics). Below rank ten, counts drop further to the 90–120 range, indicating a long tail of smaller participants rather than a duopoly or oligopoly.
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 1 | 4D Pharma Research Ltd | 389 | |
| 2 | Evelo Biosciences Inc | 254 | |
| 3 | Société des Produits Nestlé SA | 245 | |
| 4 | Regents of the University of California | 238 | |
| 5 | SNIPR Tech | 237 | |
| 6 | INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (I… | 197 | |
| 7 | Massachusetts Institute of Technology | 178 | |
| 8 | The Broad Institute Inc | 172 | |
| 9 | Finch Therapeutics Holdings LLC | 136 | |
| 10 | Seres Therapeutics Inc | 128 |
| # | Applicant | Patent families | Share |
|---|---|---|---|
| 11 | Memorial Sloan Kettering Cancer Center | 120 | |
| 12 | Seed Health Inc | 120 | |
| 13 | SNIPR Biome ApS | 118 | |
| 14 | Glycosyn LLC | 116 | |
| 15 | DSM IP Assets BV | 111 | |
| 16 | Ghent University | 110 | |
| 17 | Board of Regents, The University of Texas System | 105 | |
| 18 | Synlogic Operating Co Inc | 103 | |
| 19 | Pendulum Therapeutics Inc | 102 | |
| 20 | The General Hospital Corporation | 96 |
The leader’s position (389 families) is roughly 1.5× the nearest commercial challenger, but several academic and research institutions—UC Regents, MIT, the Broad Institute—sit within the top eight, indicating that the IP landscape is co-shaped by public-sector research alongside dedicated biotech firms.
Filing counts for 2024–2026 are under-represented due to standard patent publication lag of 18–24 months and should not be interpreted as a further structural decline. Longer-window growth, applicant concentration, and technology-route coverage are therefore more reliable signals than the latest-year bar alone.
Filings peaked in 2020 and have eased; medicinal preparations dominate the technology mix
The annual filing trend shows how activity has evolved since 2017, while the technology composition chart reveals where IP effort is concentrated across IPC classes.
Annual filing trend
Annual filings grew from 1,072 in 2017 to a peak of 1,506 in 2020, then eased to 1,358 in 2022 and 1,071 in 2023. Counts for 2024 (790) and 2025 (537) are materially affected by publication lag and should be treated as floor estimates rather than true activity levels. The field is best characterised as past its 2020 peak, with annual volume easing on a multi-year basis.
↗ Hover for values · click a bar to ask EurekaTechnology composition
Medicinal preparations (A61K) and therapeutic activity of compounds (A61P) together account for the two largest IPC branches by a wide margin, reflecting the predominantly drug-development orientation of the corpus. Microorganism and genetic engineering filings (C12N) form a substantial third cluster. Lower-density branches—functional foods (A23L), diagnostic enzymology (C12Q), and peptides (C07K)—represent adjacent areas where filing intensity is comparatively sparse.
↗ Hover for values · click a bar to ask EurekaHighly cited patent families surfaced by the query
Citation-heavy patent families returned by the query. Use this section as citation context, not as a curated list of the most topic-specific patents.
Compositions and methods for treating gastrointest…
Aspects of the disclosure encompass compositions and therapeutic methods for treating subjects having gastrointestinal disorders. The compositions provided herein can be formulated as live biotherapeutic products (LBP), fecal microbiota transplant (FMT) products and FMT enrichment compositions, probiotics and food products, and comprise one or more of the… (excerpt from the patent abstract)
| # | Patent | Citations |
|---|---|---|
| 1 | Compositions for fecal floral transplantation and … | 325 |
| 2 | Bacterium for use as a probiotic for nutritional a… | 293 |
| 3 | Gut microbiome as a biomarker and therapeutic targ… | 278 |
| 4 | Synergistic bacterial compositions and methods of … | 248 |
| 5 | Compositions for the restoration of a fecal microb… | 248 |
| 6 | Compositions and methods | 234 |
| 7 | The gut microbiome as a biomarker and therapeutic … | 233 |
| 8 | Probiotic and prebiotic compositions, and methods … | 218 |
Ranked by total forward citations. Citation counts favour older and broadly cited patent families, and broad or adjacent patents may appear when they match the search scope. Treat this section as citation context, not as a curated list of the most topic-specific patents.
What the structure implies for R&D investment decisions
Four structural signals—maturity stage, concentration, collaboration patterns, and geographic reach—combine to characterise where risks and opportunities sit in this field.
Past-peak field with easing annual volume
The lifecycle evidence places microbiome therapeutics in a decline stage: annual filings peaked at 1,506 in 2020 and have eased since, with the recent-window growth rate at -20%. This does not preclude sub-segment growth, but entrants should expect intensifying prosecution competition on core medicinal-preparation claims and should target differentiated positions in less-saturated IPC branches.
Post-peakModerate concentration with a mixed public-private top tier
The top five filers hold 20% of the hundred largest filers’ combined output—moderate concentration that leaves room for mid-tier challengers. Notably, four of the top eight positions are held by universities or research institutes (UC Regents, INSERM, MIT, the Broad Institute), meaning a significant share of foundational IP originates outside dedicated biotech firms and may be available for licensing.
Moderate concentrationMIT–Broad and INSERM-led French consortia are the most active co-filers
The most prolific co-filing pair is MIT and the Broad Institute (148 joint patent families), reflecting their shared CRISPR and genetic engineering infrastructure. INSERM is the hub of a second major cluster, co-filing with the University of Rouen (59 families), Rouen University Medical Centre (57), the University of Paris-Saclay (48), Institut Gustave Roussy (47), and CNRS (39), among others. Firms seeking to access foundational academic IP should map these consortium relationships carefully.
Consortium-drivenUS-centric filing with meaningful PCT and EPO coverage
The United States is the leading filing jurisdiction, followed by WIPO (PCT) and the European Patent Office. Australia, Canada, and Israel also carry substantial records, indicating that innovators are pursuing broad international protection strategies. China’s comparatively low count suggests either limited commercial targeting of that market or a gap that competitors could exploit.
US-led, global spreadGo beyond the landscape: Eureka’s TRIZ Solution agent breaks down an R&D problem and returns patented concept solutions, each with a technical approach and cited patent & literature evidence.
| Applicant | Collaborator | Co-filings |
|---|---|---|
| Massachusetts Institute of Technology | The Broad Institute Inc | 148 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | University of Rouen | 59 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | Rouen University Medical Centre | 57 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | University of Paris-Saclay | 48 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | Institut Gustave Roussy | 47 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | CNRS (Centre National de la Recherche Scientifique) | 39 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | INRAE (Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement) | 29 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | Assistance Publique – Hôpitaux de Paris (APHP) | 27 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | Sorbonne University | 22 |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | Université Paris Cité | 21 |
Co-filing pairs, ranked by the number of jointly-filed patent families.
4D Pharma and Nestlé lead by volume; divergent trajectories separate declining specialists from rising platform players
The top applicants divide into two strategic profiles: therapeutics-focused biotechs concentrated in medicinal preparations and immune/CNS indications, and diversified platform players expanding across functional foods and formulations.
4D Pharma Research
4D Pharma Research holds 389 patent families—the largest position in the corpus—focused tightly on medicinal preparations (A61K 35), CNS therapeutics (A61P 25), and immunological activity (A61P 37). Its momentum is sharply negative (▼ –96% in recent filings vs prior period), signalling that its portfolio build-out phase has concluded and prosecution activity has decelerated markedly. This makes its existing estate a potential licensing target rather than a growing competitive threat.
families: 389Nestlé (Société des Produits Nestlé SA)
Nestlé ranks third overall with 245 patent families, but its momentum trajectory is the strongest of any tracked applicant (▲ 4.8× vs prior 3-year period), indicating an accelerating filing programme. Its technology focus spans medicinal preparations (A61K 35), functional food ingredients (A23L 33), and small-molecule preparations (A61K 31), reflecting a dual strategy that bridges pharmaceutical-grade microbiome products with consumer nutrition—a differentiated and defensible position relative to pure-play biotech competitors.
families: 245| Applicant | Recent (3 yrs) | Trend |
|---|---|---|
| 4D Pharma Research Ltd | 8 | ▼ -96% |
| Evelo Biosciences Inc | 55 | ▼ -65% |
| SNIPR Tech | 32 | ▼ -47% |
| Regents of the University of California | 75 | ▬ +4% |
| Société des Produits Nestlé SA | 129 | ▲ 4.8× vs prior 3-yr |
| INSERM (Institut National de la Santé et de la Recherche Médicale) | 52 | ▲ 4.0× vs prior 3-yr |
| Massachusetts Institute of Technology | 63 | ▼ -27% |
| The Broad Institute Inc | 64 | ▼ -24% |
Under-served branches in functional foods, diagnostics, and peptides worth monitoring
Several IPC branches adjacent to the dominant A61K/A61P core show meaningfully lower filing density. These observations reflect relative sparsity in the current corpus; whether they represent genuine entry opportunities depends on technical fit and commercial pathway.
A23L · Foods & non-alcoholic beverages
This branch holds the largest count among the lower-density adjacencies but represents only 8% of the corpus relative to its potential overlap with microbiome-modulating nutritional products. The plausible technical rationale is strong—prebiotic fibre formulations, fermented food ingredients, and synbiotic food systems all sit here. Nestlé’s accelerating filing momentum and dual A61K/A23L focus suggests a first-mover is already claiming ground; others considering this adjacent should assess freedom-to-operate carefully and move promptly.
Search this in Eureka →C12Q · Measuring & testing involving enzymes/DNA
Diagnostic and companion-diagnostic applications—microbiome sequencing assays, biomarker panels for treatment stratification—sit in C12Q and account for a comparatively sparse 4% share of the corpus. As regulatory pressure to stratify microbiome therapy recipients by baseline microbiota composition increases, diagnostic IP in this branch has plausible commercial value as a gateway to the therapeutic product. Entry paths include co-development agreements with sequencing platform providers or in-licensing of foundational assay patents from academic co-filers in the INSERM consortium.
Search this in Eureka →How leaders differ by technology route across IPC branches
Strength of each leader across the main technology routes.
| Player | A61K 35 · Medicinal preparations | A61P 1 · Therapeutic activity of compounds | A61K 31 · Medicinal preparations | C12N 1 · Microorganisms & genetic engineering | A23L 33 · Foods & non-alcoholic beverages |
|---|---|---|---|---|---|
| 4D Pharma Research Ltd | Strong · 414 | Moderate · 141 | Absent | Moderate · 115 | Moderate · 141 |
| Société des Produits Nestlé SA | Strong · 156 | Moderate · 71 | Strong · 136 | Moderate · 41 | Strong · 155 |
| SNIPR Tech | Strong · 128 | Absent | Strong · 180 | Moderate · 70 | Absent |
| Evelo Biosciences Inc | Strong · 261 | Absent | Absent | Moderate · 78 | Absent |
| Regents of the University of California | Strong · 165 | Moderate · 57 | Moderate · 53 | Absent | Moderate · 44 |
| Ghent University | Strong · 105 | Strong · 87 | Absent | Moderate · 43 | Absent |
| Seres Therapeutics Inc | Strong · 151 | Absent | Absent | Moderate · 56 | Absent |
Frequently asked questions
The evidence covers 10,017 patent families in scope globally, spanning medicinal preparations, genetic engineering, functional foods, diagnostics, and adjacent branches.
4D Pharma Research Ltd leads with 389 patent families, ahead of Evelo Biosciences (254), Nestlé (245), the Regents of the University of California (238), and SNIPR Tech (237).
Annual filings reached their highest recorded level in 2020 at 1,506, then eased. Counts for 2024 and 2025 are under-represented due to the standard 18–24 month patent publication lag.
The United States leads, followed by WIPO (PCT) and the European Patent Office, with Australia, Canada, and Israel also carrying substantial records. China’s count is comparatively low.
MIT and the Broad Institute are the most prolific co-filers with 148 joint patent families. INSERM anchors a second major cluster, co-filing with multiple French academic and hospital institutions, including the University of Rouen (59 families) and Rouen University Medical Centre (57 families).
Nestlé shows the strongest momentum at 4.8× its prior 3-year filing rate, and INSERM is also expanding at 4.0× its prior rate. By contrast, 4D Pharma Research has seen a sharp deceleration (▼ -96%), suggesting its portfolio build-out phase has concluded.
Map your own microbiome IP landscape in minutes
Join 18,000+ innovators using PatSnap Eureka to map any technology landscape: search 2B+ patents and papers, surface key assignees, and generate a report like this in minutes.
Disclaimer. This page is generated from PatSnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. PatSnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.